Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | A real-world study of the optimal duration of CPX-351 treatment in patients with AML

Fabio Guolo • 15 Jun 2024
EHA 2024
Leukemia CPX-351

Fabio Guolo, MD, University of Genoa, Genoa, Italy, presents the findings of a real-world study investigating the optimal duration of CPX-351 treatment and the optimal timing for consolidation with allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fabio Guolo

Selecting patients with secondary AML for CPX-351 1:14
Selecting patients with secondary AML for CPX-351
Fabio Guolo • 13 Jun 2025
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification 1:15
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
Fabio Guolo • 13 Jun 2025
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML 1:19
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
Fabio Guolo • 6 Dec 2024
Real-world evidence of the efficacy of CPX-351 in secondary AML 1:01
Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo • 6 Dec 2024

Related Videos

Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The potential association of plasma venetoclax level with treatment efficacy in first-line AML 2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals